Japan Reconsiders Online, Mail-Order Sales Ban Of Risky Drugs
This article was originally published in PharmAsia News
Executive SummaryJapan had planned to ban online sales of nonprescription drugs deemed to have a moderate to high risk of side effects, but now is reconsidering. The Health, Labor and Welfare Ministry had said earlier the ban would include mail-order sales as well, but it still needs to form a committee to consider whether the proposal is appropriate. Internet retailers, the disabled and the general public raised such an outcry the ministry agreed to review its plan to enact the ban June 1. In addition to considering a ban, the panel also is to study other ways to address the problem of unsafe drugs sold from remote sites. The Japan Pharmaceutical Association supports a ban. (Click here for more - a subscription may be required
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.